SkinBioTherapeutics Plc (SBTX)

Overview

SkinBioTherapeutics plc is a pioneering life science company based in the United Kingdom, which operates on a global scale, including in the United States and Europe. Established in 2015 and undergoing a name change from Skinbiotix Ltd to SkinBioTherapeutics plc in December 2016, the company focuses on leveraging the human microbiome's potential to revolutionize health and skincare. Through rigorous research and development efforts, SkinBioTherapeutics has embarked on creating innovative solutions that utilize the beneficial properties of probiotic bacteria. Their work is supported by strategic agreements and research collaborations, such as with Croda Plc and the University of Manchester, where they have two ongoing research programmes; an oral programme and an inflammation study. Their aim is not only to advance skin health but also to provide solutions across various market segments including cosmetic skincare, food supplements, medical skincare, infection control, and pharmaceutical skincare.

Products and Services

SkinBioTherapeutics plc has developed a distinct range of technologies aimed at improving health and skin conditions by harnessing the power of the microbiome:

• SkinBiotix technology: A ground-breaking technology that promotes skin health by leveraging beneficial probiotic bacteria and their active components. This technology underpins a variety of applications aimed at enhancing the skin's natural defenses and maintaining its health and appearance.
• AxisBiotix technology: Focused on the intricate relationship between the gut and the skin, AxisBiotix technology is particularly aimed at individuals suffering from psoriasis. It is designed to alleviate the symptoms associated with this skin condition through the manipulation of the gut microbiome, highlighting the interconnectedness of our body systems and the potential of targeted microbial interventions in managing skin disorders.